Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8744103 | 0.91 | ALDH1A1 (0.50) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| SCHEMBL7749601 | 0.90 | ALDH1A1 (0.53) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| SCHEMBL613001 | 0.90 | ALDH1A1 (0.53) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| SCHEMBL2894347 | 0.90 | DTYMK (0.50) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| SCHEMBL611920 | 0.89 | ALDH1A1 (0.51) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| Hydrochloric Acid SCHEMBL11773238 | 0.89 | ALDH1A1 (0.51) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| SCHEMBL8526398 | 0.87 | TSHR (0.53) | TSHRCASP6DTYMKALDH1A1VCAM1 | |
| SCHEMBL1787500 | 0.87 | ALDH1A1 (0.50) | TSHRDTYMKALDH1A1VCAM1CYP3A4 | |
| SCHEMBL1964055 | 0.85 | ALDH1A1 (0.57) | TSHRDTYMKALDH1A1VCAM1CYP3A4 | |
| SCHEMBL7744994 | 0.85 | TSHR (0.44) | TSHRCASP6DTYMKALDH1A1VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103502216-B | As pesticide and acaricidal indole carboxamides and benzimidazole-carboxamide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-04 | — | — | CN | disclosed |
| US-9107411-B2 | Indolecarboxamides and benzimidazolecarboxamides as insecticides and acaricides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2900629-A2 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2015-08-05 | — | — | EP | disclosed |
| EP-2683688-B1 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES | BAYER IP GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-8906344-B2 | F-18 radiolabeled compounds for diagnosing and monitoring kidney function | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| WO-2014045306-A2 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-03-27 | — | — | WO | disclosed |
| US-20140088167-A1 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-20140086837-A1 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| EP-2683688-A1 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES | Bayer Intellectual Property GmbH (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| EP-1943229-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007048842-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| US-5130442-A | Compounds for forming color in recording material based on acid developers | BAYER AKTIENGESELLSCHAFT (DE) | 1992-07-14 | — | — | US | disclosed |
| EP-0431425-A2 | Chromogen enamine compounds, their preparation and use as colour formers | BAYER AG (DE) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | TSHR 466/4885CASP6 4663/4885DTYMK 3649/4885 |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | TSHR 35/4885CASP6 4150/4885DTYMK 4708/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | TSHR 333/4885CASP6 4381/4885DTYMK 3936/4885 |
| US-20140088167-A1 | INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES | AADAC, DDT, AANAT | TSHR 1345/4885CASP6 1644/4885DTYMK 3144/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | TSHR 35/4885CASP6 4150/4885DTYMK 4708/4885 |
| US-20140086837-A1 | F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION | SLCO1B1, SLCO1B3, SLCO2B1 | TSHR 1294/4885CASP6 3474/4885DTYMK 2604/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | TSHR 85/4885CASP6 3047/4885DTYMK 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.